Evidence map›Paper›PMID 39877415›Full record

ArticleIJID regions2025

C-reactive protein and association with disease severity in hospitalized adult patients with Lassa fever in Nigeria.

Ebenezer Oseremen Dic-Ijiewere, Danny Asogun, Festus Oloruntoba Okojie, Adoghe Patricia Omono, Okpunu Eseoleleti Christopher, Adam Zumla, Rizwan Ahmed, Faith Huemomen Unuabonah, Joseph Okoeguale, Cyril Erameh and 10 more

Abstract read
In one paragraph

Article in IJID regions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Ebenezer Oseremen Dic-IjiewereDepartment of Chemical Pathology, College of Medicine, Ambrose Alli University, Ekpoma, Nigeria.
Danny AsogunInstitute of Viral and Emergent Pathogens, Irrua Specialist Teaching Hospital, Ekpoma, Nigeria.
Festus Oloruntoba OkojieDepartment of Chemical Pathology, College of Medicine, Ambrose Alli University, Ekpoma, Nigeria.
Adoghe Patricia OmonoDepartment of Chemical Pathology, College of Medicine, Ambrose Alli University, Ekpoma, Nigeria.
Okpunu Eseoleleti ChristopherDepartment of Community medicine, Irrua Specialist Teaching Hospital, Irrua, and Faculty of Clinical Sciences, Ambrose Alli University, Ekpoma, Nigeria.
Adam ZumlaRoyal Bolton Hospital, Bolton NHS Foundation Trust, Bolton, United Kingdom.
Rizwan AhmedRoyal Bolton Hospital, Bolton NHS Foundation Trust, Bolton, United Kingdom.
Faith Huemomen UnuabonahDepartment of Haematology, Irrua Specialist Teaching Hospital, Irrua & Department of Haematology, Ambrose Alli University, Ekpoma, Nigeria.
Joseph OkoegualeInstitute of Viral and Emergent Pathogens, Irrua Specialist Teaching Hospital, Ekpoma, Nigeria.
Cyril EramehInstitute of Viral and Emergent Pathogens, Irrua Specialist Teaching Hospital, Ekpoma, Nigeria.
Ephraim OgbaininInstitute of Viral and Emergent Pathogens, Irrua Specialist Teaching Hospital, Ekpoma, Nigeria.
Sylvanus OkogbeninInstitute of Viral and Emergent Pathogens, Irrua Specialist Teaching Hospital, Ekpoma, Nigeria.
Reuben EifediyiInstitute of Viral and Emergent Pathogens, Irrua Specialist Teaching Hospital, Ekpoma, Nigeria.
Linzy EltonDivision of Infection and Immunity, Centre for Clinical Microbiology, University College London, London, United Kingdom.
Isobella HoneyborneDivision of Infection and Immunity, Centre for Clinical Microbiology, University College London, London, United Kingdom.
John TemboHerpeZ and PANDORA-D-NET, University Teaching Hospital, Lusaka, Zambia.
Francine NtoumiFondation Congolaise Pour la Recherche Médicale, Brazzaville, Republic of Congo.
Najmul HaiderSchool of Life Sciences, Faculty of Natural Sciences, Keele University, Keele, United Kingdom.
Timothy D McHughDivision of Infection and Immunity, Centre for Clinical Microbiology, University College London, London, United Kingdom.
Alimuddin ZumlaDivision of Infection and Immunity, Centre for Clinical Microbiology, University College London, London, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Lassa fever (LF) poses a significant health burden in West Africa. The pathophysiology of LF and determinants of clinical spectrum of disease remain poorly understood. We performed a study to understand the correlation of blood inflammatory marker C-reactive protein (CRP), with LF disease severity. Methods: A cross-sectional controlled study of adult patients with LF presenting to the Institute of Lassa Fever Research and Control at Irrua Specialist Teaching Hospital, Nigeria between January and April 2023. LF was confirmed using real-time polymerase chain reaction. Disease severity was classified as: severe disease = blood urea level >100 mg/dl and moderate disease = <100 mg/dl. CRP was measured using Tecan Infinite F50 ELISA system. Disease severity was correlated with CRP levels. Results: A total of 64 adult patients with LF and 60 healthy controls were enrolled. There was no difference in the mean age (37.6 vs 35.2 years, Conclusions: Inpatients with LF showed significant inflammation and elevated CRP levels, which correlated with disease severity. CRP could serve as a potential baseline marker in outbreak situations to trigger management decision-making to treat or not to treat considering limited ribavirin supplies. Given the inflammatory changes and correlation of elevated CRP levels with LF disease severity, larger controlled studies during outbreaks are required to assess use of CRP for more accurate triaging, including commencement of treatment.

Indexed as

BiomarkersC-reactive protein (CRP) inflammationDisease severityFeverLassaLassa fever virus

Identifiers

PMID39877415
PMCPMC11772983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.